INTRODUCTION
In the US, an estimated 26 million people have diabetes, approximately 8% of the entire population [1] . Diabetic complications are an important medical and public health concern, as diabetes is associated with kidney failure, limb amputation, blindness, heart disease, and stroke [1] . Appropriate disease management, primarily maintenance of glycated hemoglobin (HbA1c) levels below 7% can decrease the risk of microvascular complications [2] . Current treatments for type 2 diabetes mellitus (T2DM) include lifestyle and dietary modifications, oral antidiabetic medications, non-insulin injectables, and insulin [2, 3] . For patients with mild hyperglycemia, lifestyle change and monotherapy with metformin or an acceptable alternative, such as a dipeptidyl peptidase-4 inhibitor (DPP-4i), are recommended [3] .
Sulfonylureas (SUs) and thiazolidinediones (TZDs) can also be prescribed, although it has been suggested that the additional risks associated with these drug classes should be considered [3] . The American Diabetes Medicare Part D plan quality measure [4] . Increased adherence to medications is associated with a decrease in HbA1c [5] [6] [7] [8] ,
lower odds of mortality [7] , fewer all-cause hospitalizations [7] , and lower healthcare expenditures [9] [10] [11] [12] . These improvements in outcomes may translate into substantial benefit to the healthcare system, averting a projected 699,000 emergency room visits and 341,000
hospitalizations per year, resulting in a savings of nearly $5 billion [13] . Despite the noted impact of good adherence, a systematic review found a wide range of adherence rates across retrospective studies, with rates ranging from 36% to 93% [14] . A second review found that when combining study results, only 58% of patients were considered adherent [15] . To date, the majority of interventions to improve adherence to diabetes medications have focused on education and one-on-one counseling [16] . Several factors associated with adherence to antidiabetic medications have been identified in the literature. Younger age, female gender, residence in the Southern region of the US, and high cost-sharing have been associated with lower adherence in multiple analyses [10, 17, 18] . Additional factors include depression, polytherapy, and twice-daily regimens [14] .
Analyses have also compared patients initiating specific non-insulin antidiabetic drugs and drug classes in terms of adherence and persistence, including metformin, SUs, glucagon-like peptide-1 receptor agonists (GLP1RAs), TZDs, and DPP-4is [10, 17, 19, 20] .
To our knowledge, no US-based analyses comparing adherence to and persistence with DPP-4is as a medication class with other classes of antidiabetic medications have been reported. Therefore, the objective of this analysis was to compare adherence and persistence among patients initiating DPP-4is, SUs, and TZDs over 1-and 2-year follow-up periods. Additional objectives were to compare adherence and persistence between patients initiating saxagliptin and sitagliptin and to describe treatment patterns following initiation.
METHODS

Data Source
This retrospective, observational cohort study used administrative claims data from the annually for each study drug for each insurance plan in the database, and index regimen [24] . A patient's initial regimen was 
RESULTS
Patient Selection
Patient attrition is presented in Fig 
Descriptive Analysis
Demographic, clinical, and treatment characteristics are presented in Tables 1 and 2. The average age of patients in the sample was 56.7 years (standard deviation [SD] 12.2), and 54.3% were men. The majority of patients were insured through a commercial plan (77.7%). Approximately, one-fifth (20.3%) had evidence of macrovascular disease in the pre-period. Metformin use was common in the pre-period (55.0%), whereas insulin use was less common (6.7%). There were significant differences in baseline characteristics among the three drug class cohorts. DPP-4i initiators were younger on average than SU initiators but older than TZD initiators, and a greater proportion were women than both SU and TZD initiators. The proportion of patients using metformin in the pre-period was higher among DPP-4i initiators, and a greater proportion of patients initiated a study drug that was part of a fixed-dose combination with metformin. A mail-order index prescription was more common among DPP-4i initiators, whereas initiating monotherapy was less common. Significant differences were also found between the saxagliptin and sitagliptin initiators. On average, saxagliptin initiators were younger and more commonly insured through commercial plans. Unadjusted adherence and persistence results are presented in Table 3 . Over the 1-year follow-up period, a significantly greater proportion of DPP-4i initiators were adherent to index drug class than SU and TZD initiators. This relationship was consistent over the 2-year follow-up period and in the monotherapy and the non-mail-order sub-samples. Significantly more DPP-4i initiators were persistent with index drug class during the 1-year follow-up period than SU initiators and TZD initiators. As with adherence, this was true over the 2-year Table 1 continued Table 2 continued Table 3 Unadjusted adherence and persistence Patients may discontinue their oral antidiabetic medication following the onset of adverse events particular to their medication, Fig. 3 Adjusted odds ratio for being adherent (PDC C 0.80) by index drug class and index drug within DPP-4i cohort for 1-and 2-year follow-up among full study sample and sub-samples of monotherapy and non-mailorder patients. Models controlled for age, sex, presence of capitated services, payer, region, urbanicity, plan type, indicator for fixed-dose metformin index drug, indicator for index drug filled via mail order, index drug regimen (monotherapy, index drug plus additional non-insulin antidiabetic drugs, index drug plus insulin), baseline total expenditures and diabetes prescription expenditures, index diabetes medication class cost-sharing, baseline endocrinologist and cardiologist visits, baseline renal impairment, baseline macrovascular and microvascular disease, pregnancy during follow-up, baseline number of unique 3-digit ICD-9 diagnoses and Charlson Comorbidity Index. AOR Adjusted odds ratio, CI Confidence interval, DPP-4i Dipeptidyl peptidase-4 inhibitor, PDC Proportion of days covered, SU Sulfonylurea, TZD Thiazolidinedione such as hypoglycemia while on an SU [25, 26] . Additionally, clinicians may discontinue a medication when the patient develops a comorbidity that places the patient at greater risk for an adverse event with a particular medication, for example, a patient at increasing risk for fractures on a TZD [27] .
Potential explanations for the observed association between initiation of DPP-4is and better adherence and persistence include a better tolerability profile compared with SUs, which are associated with weight gain and hypoglycemia, and TZDs, which are associated with weight gain and bone fracture [3] . Fig. 4 Adjusted curves for time to discontinuation by index drug class for 1-and 2-year follow-up and within subsamples of monotherapy and non-mail-order patients for 1-year follow-up. a Adjusted curves and hazard ratios for discontinuation of index drug class over 1-year follow-up period. b Adjusted curves and hazard ratios for discontinuation of index drug class over 2-year follow-up period. c Adjusted curves and hazard ratios for discontinuation of index drug class over 1-year follow-up period among monotherapy patients. d Adjusted curves and hazard ratios for discontinuation of index drug class over 1-year follow-up period among non-mail-order patients. Models controlled for age, sex, presence of capitated services, payer, region, urbanicity, plan type, indicator for fixed-dose metformin index drug, indicator for index drug filled via mail order, index drug regimen (monotherapy, index drug plus additional non-insulin antidiabetic drugs, index drug plus insulin), baseline total expenditures and diabetes prescription expenditures, index diabetes medication class cost-sharing, baseline endocrinologist and cardiologist visits, baseline renal impairment, baseline macrovascular and microvascular disease, pregnancy during follow-up, baseline number of unique 3-digit ICD-9 diagnoses and Charlson Comorbidity Index. AHR Adjusted hazard ratio, CI Confidence interval, DPP-4i Dipeptidyl peptidase-4 inhibitor, SU Sulfonylurea, TZD thiazolidinedione Differences noted between saxagliptin and sitagliptin may be due in part to a one-step dose adjustment for patients with renal impairment for saxagliptin, compared with a two-step dose adjustment for sitagliptin [28, 29] . However, more research utilizing additional types of data sources is needed to specifically test these hypotheses for the differences in adherence and persistence between drug classes and DPP-4i-specific drugs.
An analysis conducted by Rathmann et al. [20] comparing DPP-4is and SUs reported results consistent with the findings presented here.
Utilizing data from general practices in Germany, researchers found that the risk of discontinuation was higher for DPP-4i initiators Fig. 5 Adjusted curves for time to discontinuation by index drug for 1-and 2-year follow-up and within subsamples of monotherapy and non-mail-order patients for 1-year follow-up. a Adjusted curves and hazard ratios for discontinuation of index drug over 1-year follow-up period. b Adjusted curves and hazard ratios for discontinuation of index drug over 2-year follow-up period. c Adjusted curves and hazard ratios for discontinuation of index drug over 1-year follow-up period among monotherapy patients. d Adjusted curves and hazard ratios for discontinuation of index drug over 1-year follow-up period among nonmail-order patients. Models controlled for age, sex, presence of capitated services, payer, region, urbanicity, plan type, indicator for fixed-dose metformin index drug, indicator for index drug filled via mail order in monotherapy samples, index drug regimen (monotherapy, index drug plus additional non-insulin antidiabetic drugs, index drug plus insulin) in non-mail-order samples, baseline total expenditures and diabetes prescription expenditures, index diabetes medication class cost-sharing, baseline endocrinologist and cardiologist visits, baseline renal impairment, baseline macrovascular and microvascular disease, pregnancy during follow-up, baseline number of unique 3-digit ICD-9 diagnoses and Charlson Comorbidity Index. AHR Adjusted hazard ratio, CI Confidence interval, DPP-4i Dipeptidyl peptidase-4 inhibitor in the first 3 months and then fell below that of SU initiators for the remainder of follow-up, a maximum of 2 years [20] . Using US health insurance claims, Curkendall et al. [10] evaluated adherence and persistence over 1-year follow-up between patients initiating saxagliptin and patients initiating an SU, TZD, or GLP-1RA. These investigators found that patients initiating saxagliptin had greater odds of being adherent and lower risk of discontinuation than patients initiating medications within the other three drug classes [10] . No analyses over a 2-year followup or within monotherapy or non-mail-order subgroups were conducted [10] . Beyond adherence and persistence, Rathmann et al. [20] found that compared with SUs, initiating a DPP-4i was associated with lower risk of hypoglycemia and newly diagnosed macrovascular outcomes, including coronary heart disease, myocardial infarction, and stroke.
This study has limitations that should be recognized. Administrative claims data are not 
CONCLUSIONS
Patients initiating DPP-4is were more adherent to and persistent with the index drug class than patients initiating SUs or TZDs. These findings were robust to sensitivity analyses. Similarly, patients initiating saxagliptin were more likely to be adherent and persistent than patients 
